Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 5/20 | 0.41 |
| ▸ | RARA | P10276 | 2/20 | 0.40 |
| ▸ | RARG | P13631 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 2/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12625537 | 1.00 | RARB (0.41) | RARBRARARARGALOX5APFEN1 | |
| SCHEMBL12625542 | 0.99 | RARB (0.42) | RARBRARARARGALOX5APFEN1 | |
| SCHEMBL12625540 | 0.99 | RARB (0.42) | RARBRARARARGALOX5APFEN1 | |
| SCHEMBL12624785 | 0.99 | RARB (0.42) | RARBRARARARGALOX5APFEN1 | |
| SCHEMBL12625545 | 0.99 | RARB (0.42) | RARBRARARARGALOX5APFEN1 | |
| SCHEMBL12624783 | 0.99 | RARB (0.42) | RARBRARARARGALOX5APFEN1 | |
| SCHEMBL12625541 | 0.99 | RARB (0.42) | RARBRARARARGALOX5APFEN1 | |
| SCHEMBL12624787 | 0.99 | RARB (0.42) | RARBRARARARGALOX5APFEN1 | |
| SCHEMBL12624780 | 0.99 | RARB (0.42) | RARBRARARARGALOX5APFEN1 | |
| SCHEMBL12624784 | 0.99 | RARB (0.42) | RARBRARARARGALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10011773-B2 | Liquid crystal display device | DIC CORPORATION (JP) | 2018-07-03 | — | — | US | disclosed |
| US-9809752-B2 | Liquid crystal display device | DIC CORPORATION (JP) | 2017-11-07 | — | — | US | disclosed |
| US-20160215217-A1 | LIQUID CRYSTAL DISPLAY DEVICE | DIC CORPORATION (JP) | 2016-07-28 | — | — | US | disclosed |
| US-20160130502-A1 | LIQUID CRYSTAL DISPLAY DEVICE | DIC CORPORATION (JP) | 2016-05-12 | — | — | US | disclosed |
| EP-2116522-B1 | PENTACYCLIC LIQUID CRYSTAL COMPOUND HAVING CF<SB>2</SB>O BONDING GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY | JNC CORP (JP) | 2013-09-18 | — | — | EP | disclosed |
| EP-2116522-B1 | PENTACYCLIC LIQUID CRYSTAL COMPOUND HAVING CF<SB>2</SB>O BONDING GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY | JNC CORP (JP) | 2013-09-18 | — | — | EP | disclosed |
| US-7951433-B2 | Five-ring liquid crystal compound having CF2O bonding group, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7951433-B2 | Five-ring liquid crystal compound having CF2O bonding group, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7879413-B2 | Chiral dopant and a liquid crystal compound with difluoromethoxy binding; wide temperature range of liquid crystal phase, large optical anisotropy and large dielectric anisotropy; stable to heat and light; short response time, low power consumption, large contrast and low driving voltage | CHISSO CORPORATION (JP) | 2011-02-01 | — | — | US | disclosed |
| US-20100127211-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND HAVING CF20 BONDING GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100127211-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND HAVING CF20 BONDING GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2116522-A1 | PENTACYCLIC LIQUID CRYSTAL COMPOUND HAVING CF<SB>2</SB>O BONDING GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY | Chisso Corporation (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20090059157-A1 | OPTICALLY ISOTROPIC LIQUID CRYSTAL MEDIUM AND OPTICAL DEVICE | CHISSO PETROCHEMICAL CORPORATION (JP) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100127211-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND HAVING CF20 BONDING GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CFAP20, KIF20A, KIF20B | RARB 2364/4885RARA 1623/4885RARG 2760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.